drugset
drugset / Trial / NCT04294251

Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

NCT04294251 ↗

Phase 3 Completed 180 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

This Study is A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

Timeline

Start
2020-03-04
Primary completion
2021-01-07
Completion
2021-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PrabotulinumtoxinA Protein / enzyme biologic — Intramuscular

Indications

masticatory muscles, hypertrophy of